Deerfield Management Company, an investment firm dedicated to advancing healthcare through information, investment, and philanthropy, and Droia Ventures, a specialist investor, dedicated to making an impact and save patient lives, led a $80m Series C funding round in Frontier Medicines, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, with participation from Galapagos, DCVC Bio, MPM Capital, and RA Capital Management. "At Galapagos, we are focused on breakthrough science and innovation to address high unmet medical needs. Frontier Medicines is a leading chemoproteomics company with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach. The participation in Frontier Medicines' Series C round aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world," Dr. Paul Stoffels, Galapagos CEO and Chairman of the Board of Directors.